About neuropace inc - NPCE
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.
NPCE At a Glance
NeuroPace, Inc.
455 North Bernardo Avenue
Mountain View, California 94043
| Phone | 1-650-237-2700 | Revenue | 99.99M | |
| Industry | Medical Specialties | Net Income | -21,465,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 25.13% | |
| Fiscal Year-end | 12 / 2026 | Employees | 209 | |
| View SEC Filings |
NPCE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.053 |
| Price to Book Ratio | 27.24 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -35.79 |
| Enterprise Value to Sales | 5.151 |
| Total Debt to Enterprise Value | 0.138 |
NPCE Efficiency
| Revenue/Employee | 478,401.914 |
| Income Per Employee | -102,703.349 |
| Receivables Turnover | 6.811 |
| Total Asset Turnover | 0.693 |
NPCE Liquidity
| Current Ratio | 5.281 |
| Quick Ratio | 4.332 |
| Cash Ratio | 3.428 |
NPCE Profitability
| Gross Margin | 77.231 |
| Operating Margin | -16.34 |
| Pretax Margin | -21.468 |
| Net Margin | -21.468 |
| Return on Assets | -14.876 |
| Return on Equity | -158.741 |
| Return on Total Capital | -23.885 |
| Return on Invested Capital | -25.669 |
NPCE Capital Structure
| Total Debt to Total Equity | 372.219 |
| Total Debt to Total Capital | 78.823 |
| Total Debt to Total Assets | 36.526 |
| Long-Term Debt to Equity | 361.095 |
| Long-Term Debt to Total Capital | 76.468 |